JP7542543B2 - 若年性特発性関節炎を治療するための抗il-6受容体抗体 - Google Patents

若年性特発性関節炎を治療するための抗il-6受容体抗体 Download PDF

Info

Publication number
JP7542543B2
JP7542543B2 JP2021544534A JP2021544534A JP7542543B2 JP 7542543 B2 JP7542543 B2 JP 7542543B2 JP 2021544534 A JP2021544534 A JP 2021544534A JP 2021544534 A JP2021544534 A JP 2021544534A JP 7542543 B2 JP7542543 B2 JP 7542543B2
Authority
JP
Japan
Prior art keywords
week
once
antibody
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021544534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519828A (ja
JP2022519828A5 (cg-RX-API-DMAC7.html
Inventor
リディ・バレ-コルメル
タンヤ・モンターヘン
ステファノ・フィオーレ
ジャネット・ヴァン・アデルスバーグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022519828A publication Critical patent/JP2022519828A/ja
Publication of JP2022519828A5 publication Critical patent/JP2022519828A5/ja
Priority to JP2024137498A priority Critical patent/JP2024161517A/ja
Application granted granted Critical
Publication of JP7542543B2 publication Critical patent/JP7542543B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2021544534A 2019-01-31 2020-01-31 若年性特発性関節炎を治療するための抗il-6受容体抗体 Active JP7542543B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024137498A JP2024161517A (ja) 2019-01-31 2024-08-19 若年性特発性関節炎を治療するための抗il-6受容体抗体

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962799698P 2019-01-31 2019-01-31
US62/799,698 2019-01-31
US201962851474P 2019-05-22 2019-05-22
US62/851,474 2019-05-22
US201962935395P 2019-11-14 2019-11-14
US62/935,395 2019-11-14
EP19306553.9 2019-12-03
EP19306553 2019-12-03
PCT/US2020/016203 WO2020160465A1 (en) 2019-01-31 2020-01-31 Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024137498A Division JP2024161517A (ja) 2019-01-31 2024-08-19 若年性特発性関節炎を治療するための抗il-6受容体抗体

Publications (3)

Publication Number Publication Date
JP2022519828A JP2022519828A (ja) 2022-03-25
JP2022519828A5 JP2022519828A5 (cg-RX-API-DMAC7.html) 2023-02-06
JP7542543B2 true JP7542543B2 (ja) 2024-08-30

Family

ID=69646033

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021544534A Active JP7542543B2 (ja) 2019-01-31 2020-01-31 若年性特発性関節炎を治療するための抗il-6受容体抗体
JP2024137498A Pending JP2024161517A (ja) 2019-01-31 2024-08-19 若年性特発性関節炎を治療するための抗il-6受容体抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024137498A Pending JP2024161517A (ja) 2019-01-31 2024-08-19 若年性特発性関節炎を治療するための抗il-6受容体抗体

Country Status (15)

Country Link
US (2) US11498969B2 (cg-RX-API-DMAC7.html)
EP (1) EP3917618A1 (cg-RX-API-DMAC7.html)
JP (2) JP7542543B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210122810A (cg-RX-API-DMAC7.html)
CN (1) CN114206442A (cg-RX-API-DMAC7.html)
AU (2) AU2020216978B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021014377A2 (cg-RX-API-DMAC7.html)
CA (1) CA3128212A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021011352A2 (cg-RX-API-DMAC7.html)
IL (1) IL284890A (cg-RX-API-DMAC7.html)
MA (1) MA54861A (cg-RX-API-DMAC7.html)
MX (1) MX2021009242A (cg-RX-API-DMAC7.html)
SG (1) SG11202107735SA (cg-RX-API-DMAC7.html)
TW (1) TWI860325B (cg-RX-API-DMAC7.html)
WO (1) WO2020160465A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024161517A (ja) * 2019-01-31 2024-11-19 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗il-6受容体抗体

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022545312A (ja) 2019-04-24 2022-10-27 サノフィ・バイオテクノロジー 関節リウマチの診断及び処置の方法
CA3142710A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
EP4593035A1 (en) * 2024-01-24 2025-07-30 Sanofi Predicting disease severity

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5216128A (en) 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
SG42954A1 (en) 1989-07-20 1997-10-17 Tadamitsu Kishimoto Antibody to human interleukin-6 receptor
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
DE07012626T1 (de) 1991-03-18 2010-01-21 New York University Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
FR2694767B1 (fr) 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
AU687763B2 (en) 1992-10-20 1998-03-05 Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service Interleukin-6 receptor antagonists
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
WO1995009873A1 (en) 1993-10-06 1995-04-13 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
AU700819B2 (en) 1994-10-07 1999-01-14 Chugai Seiyaku Kabushiki Kaisha Rheumatoid arthritis remedy containing IL-6 antagonist as effective component
PL182089B1 (en) 1994-10-21 2001-11-30 Chugai Pharmaceutical Co Ltd Pharmaceutic compositions for treating diseases caused by production of il-6
US6086874A (en) 1994-12-29 2000-07-11 Chugai Seiyaku Kabushiki Kaisha Antitumor agent effect enhancer containing IL-6 antagonist
US6261560B1 (en) 1995-02-13 2001-07-17 Chugai Seiyaku Kabushiki Kaisha Method for inhibiting muscle protein proteolysis with antibodies to interleukin-6 receptor
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
ZA971600B (en) 1996-02-26 1997-09-22 Merck & Co Inc Treatment of macular edema.
DK0923941T3 (da) 1996-06-27 2006-09-18 Chugai Pharmaceutical Co Ltd Midler mod myelom der skal anvendes sammen med nitrogensennepantitumormidler
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
KR20040024561A (ko) 1997-08-15 2004-03-20 츄가이 세이야꾸 가부시키가이샤 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는전신성 홍반성 낭창의 예방 및/또는 치료제
ATE383875T1 (de) 1998-03-17 2008-02-15 Chugai Pharmaceutical Co Ltd Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper
CA2341239C (en) 1998-08-24 2011-01-04 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for pancreatitis comprising il-6 antagonist as an active ingredient
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
EP1224189B1 (en) 1999-10-07 2006-01-25 Eli Lilly And Company Condensed dihydroquinolinone derivatives for inhibiting mrp1
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
EP1327681A4 (en) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Degraded agonist antibodies
AU1095202A (en) 2000-10-25 2002-05-06 Chugai Pharmaceutical Co Ltd Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
JP4889187B2 (ja) 2000-10-27 2012-03-07 中外製薬株式会社 Il−6アンタゴニストを有効成分として含有する血中mmp−3濃度低下剤
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
BRPI0214168B8 (pt) 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
US20060078533A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US20060078532A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060275294A1 (en) 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US20060078531A1 (en) 2004-10-12 2006-04-13 Osemwota Sota Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
ME00426B (me) 2003-04-09 2011-10-10 Genentech Inc Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
CA2539061A1 (en) 2003-09-22 2005-03-31 Biovation Gmbh & Co. Kg Use of an antagonist of il-6 for treating il-6-mediated diseases
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
CA2555688C (en) 2004-02-11 2011-11-08 Warner-Lambert Company Llc Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
AU2005247341B2 (en) 2004-05-06 2008-05-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for the treatment of uveitis
AU2005287406B2 (en) 2004-07-26 2011-08-18 Biogen Ma Inc. Anti-CD154 antibodies
US20070036788A1 (en) 2004-09-22 2007-02-15 Ahmed Sheriff Use of a compound for reducing the biological effectiveness of il-6
JPWO2006046661A1 (ja) 2004-10-28 2008-05-22 国立大学法人大阪大学 インターロイキン−6阻害剤
EP1828250A2 (en) 2004-12-16 2007-09-05 Genentech, Inc. Methods for treating autoimmune disorders
KR20080071192A (ko) 2005-11-22 2008-08-01 와이어쓰 면역글로불린 융합 단백질 제형
PL1963368T6 (pl) 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
JP2009540015A (ja) 2006-06-14 2009-11-19 イムクローン・リミテッド・ライアビリティ・カンパニー 抗egfr抗体の凍結乾燥製剤
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン.ヴェー. Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド
WO2008049897A1 (en) 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
RU2505603C2 (ru) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2009109584A1 (en) 2008-03-07 2009-09-11 Ferring International Center S. A. ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
RU2565809C2 (ru) 2009-03-19 2015-10-20 Чугаи Сейяку Кабусики Кайся Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
BR112012028557A2 (pt) 2010-05-07 2019-09-24 Xoma Technology Ltd. uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo.
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
KR101933197B1 (ko) * 2010-11-08 2018-12-27 제넨테크, 인크. 피하 투여용 항―il―6 수용체 항체
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
KR20230155586A (ko) 2013-11-22 2023-11-10 사노피 바이오테크놀로지 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
IL247942B (en) 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
US10647768B2 (en) * 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
JP7101479B2 (ja) 2014-09-16 2022-07-15 サノフィ・バイオテクノロジー 関節リウマチ患者の健康に関連した生活の質を改善するための組成物
BR112018008900A8 (pt) 2015-11-03 2019-02-26 Regeneron Pharma composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas
KR20230093522A (ko) * 2016-03-07 2023-06-27 사노피 바이오테크놀로지 류마티스 관절염의 치료를 위한 조성물 및 방법
SG11202006157VA (en) * 2018-01-05 2020-07-29 Corvidia Therapeutics Inc Methods for treating il-6 mediated inflammation without immunosuppression
JP7542543B2 (ja) * 2019-01-31 2024-08-30 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗il-6受容体抗体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Sanofi,"A Repeated Dose- nding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)",ClinicalTrials. Gov ID: NCT02991469,2016年,https://clinicaltrials.gov/study/NCT02991469
Sanofi,"An Open-label, Ascending, Repeated Dose- nding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) (SKYPP)",ClinicalTrials. Gov ID: NCT02776735,2016年
Turnier J. L. et al,"Tocilizumab for treating juvenile idiopathic artheitis",Expert Opinion on Biological Therapy,Vol. 16,2016年,559-566,doi: 10.1517/14712598.2016.1150997.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024161517A (ja) * 2019-01-31 2024-11-19 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗il-6受容体抗体

Also Published As

Publication number Publication date
MA54861A (fr) 2021-12-08
WO2020160465A1 (en) 2020-08-06
US20200339693A1 (en) 2020-10-29
CN114206442A (zh) 2022-03-18
US11498969B2 (en) 2022-11-15
JP2022519828A (ja) 2022-03-25
WO2020160465A9 (en) 2020-10-15
SG11202107735SA (en) 2021-08-30
EP3917618A1 (en) 2021-12-08
JP2024161517A (ja) 2024-11-19
MX2021009242A (es) 2021-10-26
AU2020216978A1 (en) 2021-09-09
CA3128212A1 (en) 2020-08-06
AU2025279833A1 (en) 2026-01-22
US20230127528A1 (en) 2023-04-27
TW202043285A (zh) 2020-12-01
BR112021014377A2 (pt) 2021-12-28
CO2021011352A2 (es) 2021-12-10
IL284890A (en) 2021-08-31
TW202521583A (zh) 2025-06-01
AU2020216978B2 (en) 2025-09-25
KR20210122810A (ko) 2021-10-12
TWI860325B (zh) 2024-11-01

Similar Documents

Publication Publication Date Title
US20180296670A1 (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
US20230127528A1 (en) Compositions and methods for treating juvenile idiopathic arthritis
TWI819435B (zh) 用於治療類風濕性關節炎之組成物及方法
US20250333522A1 (en) Compositions and methods for treating pain in subjects with rheumatoid arthritis
JP2017528465A (ja) 乾癬性関節炎患者における構造的損傷の進行を阻害するためのil−17アンタゴニストの使用
JP2025072440A (ja) Il-6rアンタゴニストを投与することによってリウマチ性多発筋痛症を処置するための組成物および方法
US20230174657A1 (en) Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
RU2822089C2 (ru) Антитело к рецептору il-6 для лечения ювенильного идиопатического артрита
BR122024027186A2 (pt) Anticorpo que se liga especificamente ao receptor de interleucina 6 (il-6), seu uso e composição farmacêutica, medicamento ou kit
NZ746988B2 (en) Compositions and methods for treating rheumatoid arthritis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230127

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240416

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240820

R150 Certificate of patent or registration of utility model

Ref document number: 7542543

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150